By Colin Kellaher PaxMedica shares tumbled to an all-time low on Monday after the biopharmaceutical company said it was raising $7 million in a dilutive.
PaxMedica, Inc. (PXMD) shares are spiking more than 141 percent on Tuesday morning trade after the biopharmaceutial company announced the publication of statistically significant improvements in its Autism spectrum disorder phase 2 study results.
By Chris Wack PaxMedica shares tripled to $8.52 after the company saw positive results from research exploring the potential of low-dose suramin for autism.